May 15, 2015
by Alan Franciscus, Editor-in-Chief This year’s conference had many outstanding presentations about hepatitis C drugs in development—too many to cover in one edition of the HCV Advocate newsletter. As a result, we will be covering EASL in this edition as well in the next Mid-Monthly edition. I have tried to pick out a couple of most interesting studies from the presentations from AbbVie, BMS, Gilead, and Merck.
by Jacques Chambers, CLU Even though there are some wonderful, new medications on the market, some people with HCV will still need to consider going on disability at some time in the future. For most people, it is not always easy to know when the right time to leave is. Liver disease caused by HCV is often marked by a gradual progression toward disability. As well, the emotional issues involved around leaving work and "becoming disabled" further cloud the decision-making process.
by Alan Franciscus, Editor-in-Chief
May is Hepatitis Awareness month. In this month's column, I will provide a brief overview of the five hepatitis viruses—prevalence, how they are transmitted, and how to prevent transmission. Important Note: This is a very brief overview of viral hepatitis. For detailed information about viral hepatitis see our Viral Hepatitis: The Basics.
by Alan Franciscus, Editor-in-Chief In this guide I will discuss the basics of hepatitis A, B, and C, with a bit of information on D and E that will help us to understand the similarities and differences between these viruses that all affect the liver.
**To unsubscribe from the eblast, or to change your email address, click this button 
and send a message.
To subscribe to Daily News Updates click here
Copyright © 2015 - HCV Advocate · All Rights Reserved